Latest news with #Zemidapa
Korea Herald
08-05-2025
- Business
- Korea Herald
LG Chem debuts diabetes treatment Zemidapa in Thailand
LG Chem, Korea's leading chemical company, announced Thursday that it has begun the global expansion of its new diabetes combination drug Zemidapa, marking its first export milestone with a launch in Thailand. To kick off the launch, the company hosted the 'Zemi-Connect Global' symposium in Bangkok, attended by over 120 endocrinologists from Korea, Thailand and the Philippines. The event was held alongside the International Diabetes Federation 2025 Congress, where LG Chem was a main sponsor. Zemidapa is a combination therapy that brings together Zemiglo — Korea's first domestically developed DPP-4 inhibitor — and the SGLT-2 inhibitor dapagliflozin. LG Chem prioritized the Thai market due to its direct sales infrastructure and the rapid growth of the local combination drug segment. According to pharmaceutical market research firm IQVIA MIDAS, the total market for the two inhibitors in Thailand is estimated at approximately 250 billion won ($178.7 million), with the combination drug segment growing at an average annual rate of 36 percent over the past three years. The company plans to leverage existing sales networks for Zemiglo and Zemimet, which together hold a 13 percent share of Thailand's DPP-4 segment, to generate business synergy and broaden prescription options. It also aims to enhance academic marketing and expand its local customer network. 'The demand for effective treatments for young-onset diabetes is growing in Thailand,' said Hwang In-cheol, head of LG Chem's primary care business division. 'We expect Zemidapa to meet this need and will expand into ASEAN and Latin American markets including the Philippines, Mexico and Brazil.'
Korea Herald
17-03-2025
- Business
- Korea Herald
LG Chem posts over W1tr in accumulated diabetes drug sales
LG Chem Ltd., South Korea's leading chemical company, said Monday the accumulated sales of its own diabetes drug have exceeded 1 trillion won ($688 million) in the domestic market. LG Chem sold a cumulative 1.066 trillion won worth of the Zemiglo diabetes lineup, composed of Zemiglo, Zemimet, Zemidapa and Zemiro, in South Korea for 11 years through December 2024, the company said in a press release. The company has invested 150 billion won in developing the diabetes drug lineup since 2003. It domestically launched Zemiglo in December 2012, it said. Zemiglo was the country's first diabetes drug developed by a local company. In 2024, sales of the Zemiglo lineup came to 153 billion won, up 7.3 percent from 144.5 billion won a year earlier, according to market research firm Ubist. "Separately from domestic sales, LG Chem exports about $20 billion worth of the diabetes drugs annually to countries in Southeast Asia and Latin America," a company spokesperson said. (Yonhap)
